Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery

Recruiting now · Not applicable

Conditions studied: Diabetes Mellitus Type 1

In brief

The Medtrum TouchCare Nano system with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic. However, until now, no prospective clinical study has evaluated its efficacy and safety under real-world conditions. The RENEW study is the first to address this topic.

Key facts

Study ID

NCT07320495

Run by

Charles University, Czech Republic

People needed

200

Starts

2025-06-19

Expected to finish

2028-06-19

Last updated by the study team

2026-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with T1D
• type 1 diabetes for ≥1 years
• ≥ 18 years old
• written informed consent prior to starting study related activity

You may not qualify if…

• severe noncompliance
• lactation, pregnancy, intending to become pregnant during study
• use of medication with effects on carbohydrate metabolism

Where it is running

• 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia — Prague, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.